CN110366425A - 一种预防动脉粥样硬化及其并发症的方法 - Google Patents

一种预防动脉粥样硬化及其并发症的方法 Download PDF

Info

Publication number
CN110366425A
CN110366425A CN201780078105.0A CN201780078105A CN110366425A CN 110366425 A CN110366425 A CN 110366425A CN 201780078105 A CN201780078105 A CN 201780078105A CN 110366425 A CN110366425 A CN 110366425A
Authority
CN
China
Prior art keywords
plasminogen
subject
fat
drug
atherosclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078105.0A
Other languages
English (en)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Talengen Institute of Life Sciences Co Ltd
Original Assignee
Talengen Institute of Life Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen Institute of Life Sciences Co Ltd filed Critical Talengen Institute of Life Sciences Co Ltd
Publication of CN110366425A publication Critical patent/CN110366425A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

一种预防动脉粥样硬化的方法，包括给药易患动脉粥样硬化的受试者预防有效量的纤溶酶原。以及用于预防动脉粥样硬化的包含纤溶酶原的药物、药物组合物、制品、试剂盒。

Description

PCT国内申请，说明书已公开。

Claims (47)

  1. PCT国内申请，权利要求书已公开。
CN201780078105.0A 2016-12-15 2017-06-19 一种预防动脉粥样硬化及其并发症的方法 Pending CN110366425A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/110168 2016-12-15
CN2016110168 2016-12-15
CNPCT/CN2016/110172 2016-12-15
CN2016110172 2016-12-15
PCT/CN2017/089043 WO2018107684A1 (zh) 2016-12-15 2017-06-19 一种预防动脉粥样硬化及其并发症的方法

Publications (1)

Publication Number Publication Date
CN110366425A true CN110366425A (zh) 2019-10-22

Family

ID=62557882

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201780078126.2A Pending CN110114082A (zh) 2016-12-15 2017-06-19 一种预防和治疗脂肪代谢紊乱及其相关病症的方法
CN201780078118.8A Pending CN110167583A (zh) 2016-12-15 2017-06-19 一种治疗冠状动脉粥样硬化及其并发症的方法
CN201780078127.7A Pending CN110114083A (zh) 2016-12-15 2017-06-19 一种预防和治疗脂肪肝的方法
CN201780078105.0A Pending CN110366425A (zh) 2016-12-15 2017-06-19 一种预防动脉粥样硬化及其并发症的方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN201780078126.2A Pending CN110114082A (zh) 2016-12-15 2017-06-19 一种预防和治疗脂肪代谢紊乱及其相关病症的方法
CN201780078118.8A Pending CN110167583A (zh) 2016-12-15 2017-06-19 一种治疗冠状动脉粥样硬化及其并发症的方法
CN201780078127.7A Pending CN110114083A (zh) 2016-12-15 2017-06-19 一种预防和治疗脂肪肝的方法

Country Status (7)

Country Link
US (4) US11547746B2 (zh)
EP (4) EP3556393A4 (zh)
JP (4) JP7158740B2 (zh)
CN (4) CN110114082A (zh)
CA (4) CA3046664C (zh)
TW (9) TW202123963A (zh)
WO (8) WO2018107684A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3008186A1 (en) 2015-12-18 2017-06-22 Talengen International Limited Novel method for preventing and treating angiocardiopathy
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
EP3556379A4 (en) 2016-12-15 2020-08-19 Talengen International Limited METHOD AND DRUG FOR THE PREVENTION AND TREATMENT OF OBESITY
EP3556392B1 (en) 2016-12-15 2024-04-17 Talengen International Limited Plasminogen for use in treating diabetes
CN110114080A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗皮肤纤维化的方法
JP7158740B2 (ja) 2016-12-15 2022-10-24 タレンゲン インターナショナル リミテッド 冠状動脈アテローム性硬化症およびその合併症を治療するための方法
TWI714862B (zh) 2017-06-19 2021-01-01 大陸商深圳瑞健生命科學硏究院有限公司 一種調控glp-1/glp-1r的方法和藥物
TW202140067A (zh) * 2020-02-26 2021-11-01 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療血壓異常病症的方法和藥物
CN112056563A (zh) * 2020-09-15 2020-12-11 王胜林 用于修复脂质代谢障碍的营养素组合物及其应用
CN113041247A (zh) * 2021-04-21 2021-06-29 中山大学孙逸仙纪念医院 伊玛替尼在防治新型冠状病毒及并发症药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040510A2 (en) * 2000-11-02 2002-05-23 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
CN101835483A (zh) * 2007-08-10 2010-09-15 阿费里斯股份公司 动脉粥样硬化的治疗
CN102482338A (zh) * 2009-07-10 2012-05-30 斯路姆基因公司 纤溶酶原和纤溶酶的变体

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4245051A (en) 1978-03-30 1981-01-13 Rockefeller University Human serum plasminogen activator
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
DE3515869A1 (de) 1985-05-03 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung optisch aktiver azolderivate
JPS62153224A (ja) 1985-12-27 1987-07-08 Green Cross Corp:The プラスミノゲン製剤
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
JP2764264B2 (ja) 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
AU4661493A (en) 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DK125693D0 (zh) 1993-11-05 1993-11-05 Novo Nordisk As
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
ES2435462T3 (es) 1995-07-27 2013-12-19 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
AU7951798A (en) 1997-06-26 1999-01-19 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
US7317003B2 (en) 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
US6465424B1 (en) * 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
AU3605800A (en) * 1999-02-24 2000-09-14 Henry Ford Health System An anti-angiogenic kringle protein and its mutants
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US20020159992A1 (en) 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
ATE415412T1 (de) 2001-08-10 2008-12-15 Novartis Pharma Gmbh Peptide, die atherosklerotische schädigungen binden
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
CN1408431A (zh) 2001-09-21 2003-04-09 北京华兴生生物技术有限公司 治疗与新生血管生成相关疾病的基因工程药物
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
WO2003066842A2 (de) 2002-02-06 2003-08-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen
DE10390418D2 (de) 2002-02-06 2005-01-13 N Zyme Biotec Gmbh Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
WO2004041155A2 (en) 2002-05-13 2004-05-21 Children's Hospital Los Angeles Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
AU2003234625A1 (en) 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Methods and copositions for the treatment of ischemic reperfusion
CN101396559A (zh) 2002-12-06 2009-04-01 法布罗根股份有限公司 糖尿病等的治疗
ES2325071T3 (es) 2002-12-10 2009-08-25 Wyeth Derivados del acido indol-oxo-acetilaminoacetico sustituido como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1).
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
EP1666469A4 (en) 2003-09-11 2008-12-03 Inst Med Molecular Design Inc INHIBITOR OF INHIBITOR-1 PLASMOGENIC ACTIVATOR
DE602004006437T2 (de) 2003-09-24 2008-01-10 Alstom Technology Ltd. Legierung zum löten und deren verwendung
JP4740531B2 (ja) 2003-09-30 2011-08-03 雪印乳業株式会社 骨吸収抑制剤
ATE476502T1 (de) 2004-04-22 2010-08-15 Talecris Biotherapeutics Inc Recombinant modifiziertes plasmin
US8357147B2 (en) 2005-08-17 2013-01-22 Spinal Restoration, Inc. Method for repairing intervertebral discs
FR2882654B1 (fr) * 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
WO2006095713A1 (ja) 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
EP1866416A2 (en) 2005-03-22 2007-12-19 Medstar Health Inc. Delivery systems and methods for diagnosing and treating cardiovascular diseases
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20090123582A1 (en) 2006-03-24 2009-05-14 Akiko Kuwahara Ameliorating Agent for Metabolic Syndrome
WO2008026999A2 (en) 2006-08-28 2008-03-06 Omnio Healer Ab Candidates against infection
AU2007290882B2 (en) 2006-08-28 2013-02-21 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
WO2008051794A2 (en) 2006-10-20 2008-05-02 Dow Global Technologies Inc. Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
CN101015686B (zh) 2007-02-06 2010-05-19 中国人民解放军军事医学科学院基础医学研究所 一种溶栓药物增效剂及其制备方法
US20080200387A1 (en) * 2007-02-15 2008-08-21 Hua-Lin Wu Anti-angiogenic protein, composition and use thereof
AR067446A1 (es) 2007-07-11 2009-10-14 Otsuka Pharma Co Ltd Un medicamento para tratar higado graso que comprende cilostazol
US20090239868A1 (en) 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
EP2201946A4 (en) 2007-10-23 2012-01-25 Inst Med Molecular Design Inc HAMMER OF PAI-1 PRODUCTION
BRPI0819780B1 (pt) * 2007-11-29 2023-01-24 Grifols Therapeutics Inc Polinucleotídeo e método para produzir um ou mais polipeptídeos de plasmina recombinante
BRPI0906867A2 (pt) 2008-01-09 2019-09-24 Intrexon Corp inibidores terapêuticos da função pai-1 e métodos de uso dos mesmo
US20090208448A1 (en) 2008-02-15 2009-08-20 Solomon Keith R Inhibition of angiogenesis
US20100209350A1 (en) 2008-12-30 2010-08-19 Andreas Pfuetzner Biomarkers for Adipose Tissue Activity
EP2389176A4 (en) 2009-01-23 2012-08-01 Univ Sydney NEW THERAPY FOR METABOLIC DISEASE
EP2415755A4 (en) 2009-03-31 2012-09-19 Renascience Co Ltd INHIBITOR AGENT OF PLASMINOGEN ACTIVATOR INHIBITOR 1
EP2424561A2 (en) 2009-04-30 2012-03-07 Catherine Blondel Methods for treating ocular conditions
US20110039766A1 (en) 2009-08-12 2011-02-17 Szeto Hazel H Methods for preventing or treating metabolic syndrome
CN101628113B (zh) 2009-08-18 2012-01-04 南京农业大学 蚯蚓纤溶酶抗肝纤维化的应用
CN101897925B (zh) * 2009-12-16 2015-04-29 成都百康医药工业药理毒理研究院 一种治疗代谢综合症的药物组合物
WO2011139973A2 (en) 2010-05-03 2011-11-10 Abbott Laboratories Methods of inhibiting fibrosis using anti-pai-1 antibodies
US9044458B2 (en) * 2010-08-09 2015-06-02 The Johns Hopkins University Inhibition of tat activating regulatory DNA-binding protein 43
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
DK2661493T3 (en) 2011-01-05 2016-07-18 Thrombogenics Nv PLASMINOGEN AND PLASMIN VARIANS
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
US9078904B2 (en) * 2011-02-10 2015-07-14 Trustees Of Dartmouth College Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis
EP2680837A4 (en) 2011-03-03 2015-06-03 Tersus Pharmaceuticals Llc COMPOSITIONS AND METHODS COMPRISING C16: 1N7-PALMITOLATE
CN102199587B (zh) 2011-03-24 2013-06-19 广东药学院 人纤溶酶原功能性突变体及其制备方法和应用
WO2012135729A2 (en) 2011-03-30 2012-10-04 Board Of Regents Of The University Of Texas System Methods and compositions for targeting adipose cells in mammals
CN102188699A (zh) 2011-05-06 2011-09-21 南京农业大学 一种治疗动脉粥样硬化的药物组合物及其制备方法和应用
US20120058537A1 (en) 2011-07-27 2012-03-08 Fereidoun Mahboudi Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1
KR20140064841A (ko) * 2011-08-12 2014-05-28 쓰롬보제닉스 엔.브이. 플라스미노겐 변이체 및 플라스민 변이체
CN102532326B (zh) 2011-11-18 2017-06-09 南京大学 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用
CN103656630B (zh) 2012-09-11 2015-07-08 江苏仁寿药业有限公司 一种提纯动物药材中纤溶酶并制备成中药组合物的方法
US9718760B2 (en) * 2012-10-31 2017-08-01 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof
WO2014160275A2 (en) 2013-03-14 2014-10-02 Battell Memorial Institute Biomarkers for liver fibrosis
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
US20140284520A1 (en) * 2013-03-20 2014-09-25 Elevance Renewable Sciences, Inc. Acid catalyzed oligomerization of alkyl esters and carboxylic acids
CN104274449A (zh) 2013-07-11 2015-01-14 无锡信达医疗器械有限公司 治疗肥胖症的药物组合物
TW201734054A (zh) 2013-08-13 2017-10-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
SG10201710013RA (en) 2013-08-13 2018-01-30 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
US20160199466A1 (en) 2013-08-20 2016-07-14 Trustees Of Dartmouth College Methods For Treating Tissue Fibrosis
MY202111A (en) 2014-12-19 2024-04-04 Prometic Bio Therapeutics Inc Pharmaceutical composition comprising plasminogen and uses thereof
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
WO2017101868A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
CA3008186A1 (en) 2015-12-18 2017-06-22 Talengen International Limited Novel method for preventing and treating angiocardiopathy
WO2017101869A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗肝组织损伤及其相关病症的方法
JP6749412B2 (ja) 2015-12-18 2020-09-02 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病性神経損傷及びその関連疾患を予防または治療するための方法
EP3395359B1 (en) 2015-12-18 2023-11-01 Talengen International Limited Plasminogen for use in preventing or treating acute thrombosis and chronic thrombosis
CN108463240A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗糖尿病性视网膜病变的方法
JP7158740B2 (ja) 2016-12-15 2022-10-24 タレンゲン インターナショナル リミテッド 冠状動脈アテローム性硬化症およびその合併症を治療するための方法
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
EP3556379A4 (en) 2016-12-15 2020-08-19 Talengen International Limited METHOD AND DRUG FOR THE PREVENTION AND TREATMENT OF OBESITY
TW201904990A (zh) 2017-06-23 2019-02-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040510A2 (en) * 2000-11-02 2002-05-23 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
CN101835483A (zh) * 2007-08-10 2010-09-15 阿费里斯股份公司 动脉粥样硬化的治疗
CN102482338A (zh) * 2009-07-10 2012-05-30 斯路姆基因公司 纤溶酶原和纤溶酶的变体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUTERA D等: "plasminogen isoform 1 precursor [Homo sapiens]", 《GENBANK》 *
QING XIAO等: "Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis", 《PROC. NAT. ACAD. SCI. USA》 *
尹桂芝等: "人纤溶酶原Kringle5区的基因克隆的表达及纯化", 《上海第二医科大学学报》 *

Also Published As

Publication number Publication date
TW201822810A (zh) 2018-07-01
WO2018107686A1 (zh) 2018-06-21
TW201822806A (zh) 2018-07-01
TW201822805A (zh) 2018-07-01
JP2020502156A (ja) 2020-01-23
TWI750189B (zh) 2021-12-21
WO2018107691A1 (zh) 2018-06-21
JP7161217B2 (ja) 2022-10-26
TWI746580B (zh) 2021-11-21
WO2018107690A1 (zh) 2018-06-21
TWI680764B (zh) 2020-01-01
JP2020510627A (ja) 2020-04-09
WO2018107692A1 (zh) 2018-06-21
CA3047167A1 (en) 2018-06-21
JP7214225B2 (ja) 2023-01-30
WO2018107684A1 (zh) 2018-06-21
US20190328850A1 (en) 2019-10-31
CA3047168A1 (en) 2018-06-21
US20190351033A1 (en) 2019-11-21
CA3047169A1 (en) 2018-06-21
EP3556393A1 (en) 2019-10-23
CN110114083A (zh) 2019-08-09
CN110114082A (zh) 2019-08-09
JP7160351B2 (ja) 2022-10-25
TWI684459B (zh) 2020-02-11
WO2018107687A1 (zh) 2018-06-21
US11478535B2 (en) 2022-10-25
US20200078449A1 (en) 2020-03-12
TW201822812A (zh) 2018-07-01
US11547746B2 (en) 2023-01-10
TW202123963A (zh) 2021-07-01
EP3556393A4 (en) 2020-11-25
EP3556387A4 (en) 2020-09-09
EP3556394A1 (en) 2019-10-23
JP2020511416A (ja) 2020-04-16
CA3046664A1 (en) 2018-06-21
EP3556387A1 (en) 2019-10-23
EP3556394A4 (en) 2020-11-25
TW201822809A (zh) 2018-07-01
EP3556391A4 (en) 2020-09-09
JP7158740B2 (ja) 2022-10-24
TW201822791A (zh) 2018-07-01
TW201822799A (zh) 2018-07-01
TW201822792A (zh) 2018-07-01
WO2018107688A1 (zh) 2018-06-21
WO2018107685A1 (zh) 2018-06-21
EP3556391A1 (en) 2019-10-23
CA3046664C (en) 2024-01-02
JP2020502154A (ja) 2020-01-23
CN110167583A (zh) 2019-08-23
US20200085920A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
CN110366425A (zh) 一种预防动脉粥样硬化及其并发症的方法
CN108210895A (zh) 预防动脉粥样硬化及其并发症的药物及其用途
CN110139668A (zh) 一种预防和治疗肝纤维化的方法
CN110114081A (zh) 一种改善心脏病变的方法
TWI746581B (zh) 纖溶酶原在製備預防和治療脂質腎損傷之藥劑上的用途
CN108210909A (zh) 预防和治疗脂质肾损伤的药物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination